3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)quinoline → 4-(2-((4-(Methylsulfonyl)piperazin-1-yl)methyl)-5-(quinolin-3-yl)thiazolo[5,4-d]pyrimidin-7-yl)morpholine

Participants

Role	Name	HCID	Charge
Reactant	3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)quinoline	HCID 10848590	—
Reactant	5-Chloro-2-((4-methylsulfonylpiperazin-1-yl)methyl)-7-morpholinothiazolo[5,4-d]pyrimidine	HCID 44541675	—
Product	4-(2-((4-(Methylsulfonyl)piperazin-1-yl)methyl)-5-(quinolin-3-yl)thiazolo[5,4-d]pyrimidin-7-yl)morpholine	HCID 25254152	46%

Reaction Steps

5-Chloro-2-(4-methanesulfonyl-piperazin-1-ylmethyl)-7-morpholin-4-yl-thiazolo[5,4-d]pyrimidine (130 mg) was reacted with 92 mg of 3-(4,4,5,5-tetramethyl-1,3,2,-dioxaborolan-2-yl)quinoline via General Procedure A. The product was purified by reverse phase HPLC to yield 72.6 mg of 112. MS (Q1) 526.2 (M)+.

Provenance & Evidence

DOI	10.6084/m9.figshare.5104873.v1
Patent number	US08158626B2
Source dataset	uspto-grants-2012_04
ORD ID	ord-03a4c91261e04da086da6570ec19fd26
Source note	uspto-grants-2012_04